Stockscreener 앱 받기
132.06
0.74%
-0.99
시간 외 거래:
132.20
0.14
+0.11%
전일 마감가:
$133.05
열려 있는:
$133.77
하루 거래량:
4.53M
Relative Volume:
0.72
시가총액:
$163.96B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
17.97
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
-1.49%
1개월 성능:
-5.97%
6개월 성능:
+5.63%
1년 성능:
+34.23%
1일 변동 폭
$131.81
$134.65
1주일 범위
$129.00
$137.50
52주 변동 폭
$97.86
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
132.06 | 165.19B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,006.70 | 905.79B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.80 | 554.67B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.77 | 368.38B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
184.96 | 291.13B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.77 | 285.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Prices $3 Billion of Senior Unsecured Notes - Business Wire
Gilead Sciences stock (US3755581036): Q1 earnings, FDA timing and investor focus - AD HOC NEWS
Gilead Sciences launches bond offering after acquisition spreeBloomberg By Investing.com - Investing.com Nigeria
Gilead Sciences (GILD) files for multi‑tranche senior unsecured note offering - Stock Titan
Oppenheimer Remains a Buy on Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - BioSpace
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead’s Transition Into A Long-Duration Biotech Platform (NASDAQ:GILD) - Seeking Alpha
Gilead to present liver disease data at EASL conference By Investing.com - Investing.com Canada
Gilead Sciences, Inc. $GILD Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Trek Financial LLC Purchases 13,041 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
RBC Capital Remains a Hold on Gilead Sciences (GILD) - The Globe and Mail
Bailard Inc. Has $90.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook - Yahoo Finance
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $167.00 at Rothschild & Co Redburn - MarketBeat
RBC Capital maintains Gilead Sciences stock rating on UC drug data - Investing.com
Gilead Sciences stock (US3755581036): Biotech leader navigates HIV and oncology markets - AD HOC NEWS
Gilead Sciences, Inc. (NASDAQ:GILD) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Swiss Life Asset Management Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Reports Strong HIV Growth, Raises Outlook for 2026 - Value The Markets
Kepler Cheuvreux Suisse SA Acquires New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Securian Asset Management Inc. Has $4.14 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by ABN AMRO Bank N.V. - MarketBeat
NewEdge Wealth LLC Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
JSF Financial LLC Takes $1.25 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Beat Q1 2026 Earnings and Raised Guidance. Why Is GILD Stock Still Down 17%? - TIKR.com
Stronger HIV Pipeline And Acquisition Charges Might Change The Case For Investing In Gilead Sciences (GILD) - Yahoo Finance
Leerink Partners Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $146.00 - MarketBeat
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $157 to $177 - Moomoo
Manning & Napier Advisors LLC Has $13.39 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock (US3755581036): Biotech giant eyes growth in HIV and oncology markets - AD HOC NEWS
Crossmark Global Holdings Inc. Buys 23,719 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Is Maintained at Sector Perform by RBC Capital - Moomoo
Gilead Sciences (NASDAQ:GILD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Research Alert: We Keep Our Buy Rating On Shares Of Gilead Sciences, Inc. - Moomoo
Gilead Sciences (GILD) Form 13F lists $2.12B holdings across 6 positions - Stock Titan
Gilead Sciences Price Target Raised to $157.00/Share From $155.00 by Truist Securities - Moomoo
Gilead Sciences Faces Long-Term Questions on Yeztugo Growth, RBC Capital Markets Says - Moomoo
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177 - Moomoo
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group
Truist Financial Reaffirms "Buy" Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat
Gilead Sciences’ Q1 Boosted by Biktarvy Growth and Yeztugo Launch - geneonline.com
Gilead Sciences (NASDAQ:GILD) Price Target Cut to $122.00 by Analysts at Royal Bank Of Canada - MarketBeat
Gilead posts positive Q1 buoyed by HIV drug growth - Pharmaceutical Technology
Gilead Sciences Price Target Cut to $122.00/Share From $123.00 by RBC Capital - Moomoo
Following Major Q1 Acquisitions, Gilead Readjusts Year-End Guidance - Precision Medicine Online
Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148 - marketscreener.com
Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory' - Fierce Pharma
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
0.01%
자본화:
|
볼륨(24시간):